Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Equity Average (2020 - 2025)

Historic Equity Average for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $284.7 million.

  • GeneDx Holdings' Equity Average rose 4286.78% to $284.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $284.7 million, marking a year-over-year increase of 4286.78%. This contributed to the annual value of $236.6 million for FY2024, which is 175.58% down from last year.
  • Latest data reveals that GeneDx Holdings reported Equity Average of $284.7 million as of Q3 2025, which was up 4286.78% from $267.3 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Equity Average registered a high of $599.3 million during Q3 2022, and its lowest value of -$544.2 million during Q2 2021.
  • In the last 5 years, GeneDx Holdings' Equity Average had a median value of $267.3 million in 2025 and averaged $207.7 million.
  • Per our database at Business Quant, GeneDx Holdings' Equity Average soared by 78301.09% in 2022 and then tumbled by 5408.1% in 2023.
  • Quarter analysis of 5 years shows GeneDx Holdings' Equity Average stood at $389.6 million in 2021, then increased by 4.6% to $407.5 million in 2022, then crashed by 40.83% to $241.1 million in 2023, then decreased by 6.74% to $224.9 million in 2024, then rose by 26.6% to $284.7 million in 2025.
  • Its last three reported values are $284.7 million in Q3 2025, $267.3 million for Q2 2025, and $251.3 million during Q1 2025.